Swanson R S, Sawicka J, Wood W C
Department of Surgery, Massachusetts General Hospital Cancer Center, Boston.
Surg Gynecol Obstet. 1991 Dec;173(6):465-9.
With recent changes in the management of carcinoma of the breast and a population that is increasingly aging, it behooves us to determine the most appropriate treatment of carcinoma of the breast in the elderly. We reviewed the records of 150 women 80 years of age or greater who were diagnosed between 1970 and 1980 at the Massachusetts General Hospital as having carcinoma of the breast. In these selected patients, treatment with operation or radiotherapy was well tolerated. Of the 103 patients who had mastectomies, only one patient died during the postoperative period. The complication rate from mastectomy was similar to that reported for younger patients. All of the patients who began radiotherapy completed their courses of treatment. Complications from radiotherapy were generally transient and easily tolerated. Five year actuarial survival rates for patients with Stages I and II disease were similar for those receiving primary radiation therapy (67 per cent) or modified radical mastectomy (65 per cent). However, the comparable survival rate for those treated with lumpectomy alone was only 39 per cent. Local and regional failures occurred with lumpectomy, total mastectomy or primary radiation therapy, but not with modified radical mastectomy. We conclude that age alone should not dictate the treatment for carcinoma of the breast. An otherwise healthy elderly woman should be offered the same treatment options for the treatment of carcinoma of the breast as those offered to younger patients.
随着近期乳腺癌治疗方法的改变以及人口老龄化程度的日益加深,我们有必要确定针对老年乳腺癌患者最合适的治疗方法。我们回顾了1970年至1980年间在马萨诸塞州总医院被诊断为患有乳腺癌的150名80岁及以上女性的病历。在这些选定的患者中,手术或放疗治疗的耐受性良好。在103例行乳房切除术的患者中,只有1例在术后期间死亡。乳房切除术的并发症发生率与报道的年轻患者相似。所有开始放疗的患者均完成了疗程。放疗并发症通常是短暂的,且易于耐受。接受原发性放射治疗(67%)或改良根治性乳房切除术(65%)的I期和II期疾病患者的五年精算生存率相似。然而,仅接受肿块切除术治疗的患者的可比生存率仅为39%。肿块切除术、全乳房切除术或原发性放射治疗均出现局部和区域复发,但改良根治性乳房切除术未出现。我们得出结论,不应仅根据年龄来决定乳腺癌的治疗方法。对于身体健康的老年女性,应提供与年轻患者相同的乳腺癌治疗选择。